Related Experiment Video
Updated: May 5, 2026
10:17
An Advanced Murine Model for Nonalcoholic Steatohepatitis in Association with Type 2 Diabetes
Published on: April 26, 2019
6.5K
Obesity and liver cancer
Ester Vanni1, Elisabetta Bugianesi
1Division of Gastroenterology and Hepatology, Department of Medical Sciences, University of Torino, Corso Dogliotti 14, I-10126 Torino, Italy.
Clinics in Liver Disease
|November 27, 2013
Summary
Obesity significantly increases liver cancer risk, especially hepatocellular carcinoma (HCC), often linked with nonalcoholic fatty liver disease (NAFLD). This review explores the connection and underlying mechanisms.
Area of Science:
- Hepatology
- Oncology
- Metabolic Syndrome
Background:
- Obesity is a known risk factor for various cancers, including hepatocellular carcinoma (HCC).
- Nonalcoholic fatty liver disease (NAFLD) is increasingly associated with HCC development, even in non-cirrhotic livers.
- The rising prevalence of obesity and metabolic risk factors exacerbates the risk of liver cancer.
Purpose of the Study:
- To review the current scientific evidence linking obesity to liver cancer.
- To discuss the mechanisms through which obesity contributes to the development of HCC.
- To highlight the growing public health concern regarding obesity-related liver cancer.
Main Methods:
- Literature review of existing studies on obesity, NAFLD, and HCC.
- Analysis of epidemiological data and clinical evidence.
- Synthesis of research on molecular and cellular pathways involved.
Main Results:
- Strong correlation established between obesity and increased incidence of HCC.
- Obesity promotes liver carcinogenesis through mechanisms including inflammation, insulin resistance, and altered adipokine signaling.
- NAFLD, particularly in obese individuals with diabetes, significantly elevates HCC risk.
Conclusions:
- Obesity is a critical driver of the increasing burden of liver cancer globally.
- Understanding the mechanistic links between obesity and HCC is crucial for developing effective prevention and treatment strategies.
- Public health initiatives targeting obesity may reduce the incidence of liver cancer.
Related Concept Videos
01:24Obesity
1.6K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.6K
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
330
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
330
01:26Diseases of the Liver and Gallbladder
2.1K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.1K
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
445
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
445
01:24Overview of Lipid Metabolism
7.0K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
7.0K
01:21Drug Dosing: Obese Patients
372
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
372